中国医药健康产业股份有限公司 2024 年年度股东大会文件 证券代码：600056 证券简称：中国医药 2024 年年度股东大会 会议资料 2025 年 5 月 16 日 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 中国医药健康产业股份有限公司 2024 年年度股东大会文件 议案目录 | 议案一 | 公司 2024 | 年年度报告全文及摘要 | | 1 | | --- | --- | --- | --- | --- | | 议案二 | 公司 2024 | 年度董事会工作报告 | | 2 | | 议案三 | 公司 2024 | 年度监事会工作报告 | | 14 | | 议案四 | 2024 | 年度独立董事述职报告 | | 19 | | 议案五 | 公司 2024 | 年度财务决算报告 | | 20 | | 议案六 | 关于董事及监事 | 2024 | 年度薪酬情况的议案 | 21 | | 议案七 | 公司 2024 | 年度利润分配方案 | | 22 | | 议案八 | 关于公司 2025 | | 年向银行申请综合授信额度的议案 | 23 | | 议案九 | 关于公司 2025 | | 年度为控 ...

Core Viewpoint - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size expected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and increasing demand for medicines due to aging population and improved healthcare systems [1][11]. Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect medicines, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2]. Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary services. The upstream involves the supply of materials like plastics, glass, metals, and paper, which are crucial for the manufacturing of packaging materials [3]. Industry Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation. The industry has evolved from relying on imports to adopting advanced technologies and focusing on brand building and market expansion [6]. Current Industry Status - China is the world's largest producer of plastic products, with a production volume of 77.08 million tons in 2024. The availability and pricing of plastic products directly impact the pharmaceutical packaging industry [9][11]. Market Structure - The market structure of the pharmaceutical packaging industry is diverse, with plastic packaging holding a 48% share, followed by glass packaging at 28%, metal packaging at 11%, and rubber packaging at 7% [12]. Key Enterprises Analysis - The competitive landscape of the pharmaceutical packaging industry is diverse and intense. Key players include Shandong Pharmaceutical Glass, Zhengchuan Co., Hualan Co., Haishun New Materials, and Huqiang Technology, each with unique strengths and market positions [15][18][20]. Future Development Trends - The industry is moving towards high-end and high-performance packaging materials, focusing on new technologies and innovative designs to meet the demands of high-end pharmaceuticals [22]. - Green and environmentally friendly packaging is becoming a significant trend, with companies seeking biodegradable and recyclable materials to reduce environmental impact [23]. - The industry is also undergoing consolidation and internationalization, with companies optimizing resources and expanding into international markets to enhance competitiveness [24].

Group 1 - The US has announced a 10% "baseline tariff" on all countries and a 125% tariff on China, while other countries are exempt for 90 days [1] - China exports $19.047 billion to the US, accounting for 18% of its total exports, but has a higher reliance on the "Belt and Road" initiative and the EU market [1] - If tariffs are imposed on pharmaceuticals, the burden may fall on Chinese raw material suppliers, especially if downstream clients in Europe and the US face financial difficulties [1] Group 2 - Medical devices have already seen a 20-50% tariff increase, with most companies having inventory that will buffer short-term sales [2] - Low-value consumables will face squeezed profit margins, with an average net profit margin of 13.9% for listed companies in 2024, and additional tariffs of 25-50% expected in early 2025 [2] - Many multinational pharmaceutical and medical device companies have announced plans to invest over $150 billion in the US over the next five years, indicating a long-term shift towards US pharmaceutical manufacturing [2] Group 3 - If drug exemptions are lifted, innovative drugs may focus on overseas rights sales, which have high profit margins and favorable competitive landscapes [2] - High-end medical products are expected to see increased exports to other countries, with overseas gross margins potentially offsetting tariff impacts [2] - Industries less affected by tariffs include pharmaceutical distribution, offline pharmacies, hospitals, and blood products, which primarily rely on domestic demand [2]

4月29日，上证指数收跌0.05%报3286.65点，深证成指跌0.05%，创业板指跌0.13%，北证50涨1.24%， 科创50涨0.1%，万得全A涨0.2%，万得A500跌0.15%，中证A500跌0.01%。A股成交1.04万亿，上日为 1.08万亿。 展望后市，投资者可通过半导体设备ETF（159516）、芯片ETF（512760）、集成电路ETF （159546）、科创芯片ETF国泰（589100）等产品布局AI领域的投资机会。 今日医疗板块收涨，医疗ETF（159828）收涨1.04%，美国加征关税背景下，两个变化值得注意，一个 是相关政策对于消费医疗板块的提振作用；另一个是国内反制助推核心器械国产化。从消费刺激角度来 看，早在2025年3月《提振消费专项行动方案》就曾指出，通过促进居民增收、优化"一老一小"服务供 给等举措释放医疗健康消费潜力，推动消费医疗需求扩容升级。 在技术迭代迅速、外部限制趋严、内部顶层设计支持的大背景下，人工智能相关板块有望维持高投资和 高成长，国产替代料将加速。 消息面上，据新华社报道，总书记今天在上海调研时指出，要抢抓机遇，以服务国家战略为牵引，不断 增强科技创新策源 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-031 号 中国医药健康产业股份有限公司 关于子公司原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到欧洲药品质量管理局（EDQM） （以下简称"EDQM"）核准签发的曲克芦丁（以下简称"该药品"）《欧洲药典 适用性》证书(以下简称"CEP证书")。现将有关情况公告如下： 一、CEP证书基本信息 化学原料药名称：曲克芦丁（Troxerutin） 证书编号：CEP 2023-419 - Rev 00 证书持有者及生产企业：天方药业有限公司 生产地址：河南省驻马店市驿城区光明路 2 号 发证机构：欧洲药品质量管理局（EDQM） 二、药品其他相关情况 该药品 CEP 证书的获得，标志着公司曲克芦丁产品具备以化学原料药形式进 入欧洲及承认 CEP 证书的其他规范市场的资质，将有助于公司拓展国际化业务及 增强公司产品在全球市场的 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥8,262,744,582.75, a decrease of 5.84% compared to ¥8,774,845,924.57 in the same period last year[4] - Net profit attributable to shareholders was ¥166,379,236.02, representing an increase of 14.27% from ¥145,599,951.99 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥161,389,244.66, up 14.70% from ¥140,701,002.65 in the previous year[5] - The basic and diluted earnings per share were both ¥0.1112, reflecting a growth of 14.29% compared to ¥0.0973 in the same period last year[5] - The company reported a net profit margin improvement, with net profit for Q1 2025 showing signs of recovery compared to the previous quarter[20] - The net profit for Q1 2025 was ¥227,200,028.63, compared to ¥202,880,820.28 in Q1 2024, reflecting an increase of about 12.0%[22] - The total profit for Q1 2025 was ¥304,613,642.69, up from ¥273,566,147.94 in Q1 2024, indicating a growth of approximately 11.3%[21] - The operating profit for Q1 2025 was ¥304,650,879.12, compared to ¥275,532,249.93 in Q1 2024, marking an increase of around 10.5%[21] - The total comprehensive income for Q1 2025 was ¥228,085,005.92, compared to ¥204,242,302.70 in Q1 2024, showing an increase of about 11.7%[22] Assets and Liabilities - The total assets increased by 1.16% to ¥35,691,055,852.05 from ¥35,281,058,913.54 at the end of the previous year[5] - Total liabilities increased to CNY 21,351,740,582.17 as of March 31, 2025, compared to CNY 21,170,228,649.58 at the end of 2024[17] - Non-current liabilities rose to CNY 4,127,982,443.79 as of March 31, 2025, from CNY 3,993,465,112.13 at the end of 2024[17] - Cash and cash equivalents decreased to CNY 2,769,756,319.52 as of March 31, 2025, from CNY 4,214,785,882.65 at the end of 2024[15] - Accounts receivable increased to CNY 14,304,068,583.00 as of March 31, 2025, compared to CNY 12,750,985,655.25 at the end of 2024, reflecting a 12.1% rise[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 146,543[10] - The largest shareholder, China General Technology (Group) Holding Limited, holds 31.92% of the shares, totaling 477,424,181 shares[10] Cash Flow - The net cash flow from operating activities was negative at -¥1,481,576,242.42, compared to -¥1,206,669,907.55 in the same period last year[5] - The cash flow from operating activities for Q1 2025 was -¥1,481,576,242.42, worsening from -¥1,206,669,907.55 in Q1 2024[24] - The net cash flow from financing activities for Q1 2025 was ¥46,699,455.90, a decrease from ¥237,174,487.69 in Q1 2024[25] - The company reported a foreign exchange impact on cash and cash equivalents of -¥842,648.33 in Q1 2025, compared to a positive impact of ¥13,495,949.26 in Q1 2024[25] Operational Insights - Total operating costs for Q1 2025 were CNY 7,973,445,487.28, down 6.3% from CNY 8,513,876,388.41 in Q1 2024[20] - Gross profit margin for Q1 2025 improved to 15.0% from 12.5% in Q1 2024, indicating better cost management[20] - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[20] - Investment income for Q1 2025 reached ¥7,559,129.15, a significant increase from ¥3,651,674.19 in Q1 2024, representing a growth of approximately 106.5%[21]

中国医药（600056）公告，2025年第一季度营收为82.63亿元，同比下降5.84%；净利润为1.66亿元，同 比增长14.27%。 ...

Core Insights - The implementation of policies such as "Two Invoice System" and "Volume-based Procurement" has disrupted traditional pharmaceutical distribution models, compressing profit margins for generic drugs and forcing pharmaceutical companies to shift towards specialized marketing services [1][13] - The market size of the Contract Sales Organization (CSO) industry in China is projected to reach 137.5 billion yuan in 2024, representing a year-on-year growth of 17.72%, and accounting for 32.74% of the overall pharmaceutical outsourcing market [1][13] - As competition intensifies in the pharmaceutical industry, companies are expected to focus on research and production, outsourcing sales functions to professional CSO firms to enhance market efficiency [1][13] Industry Overview - Pharmaceutical outsourcing (CXO) involves the professional outsourcing of various stages of drug discovery, clinical research, and commercialization by pharmaceutical companies, categorized into Contract Research Organizations (CRO), Contract Development and Manufacturing Organizations (CDMO), Contract Manufacturing Organizations (CMO), and Contract Sales Organizations (CSO) [2] - CSOs sign sales contracts with drug manufacturers to obtain sales rights and provide services such as market research, project consulting, promotional activities, and clinical discussions, earning revenue from consultation and service fees [3] Development Background - The Chinese government has prioritized the development of the pharmaceutical outsourcing industry, implementing numerous supportive policies that have accelerated growth, particularly in the CSO segment, which benefits from regulatory incentives [6] - Increasing regulatory scrutiny in the pharmaceutical sector has heightened compliance requirements for CSO firms, necessitating adherence to laws governing drug management, anti-competitive practices, and advertising [6] - The aging population in China has led to increased demand for pharmaceutical products, providing significant market opportunities for the CSO industry [6] Market Size and Growth - The CSO industry in China is expected to grow significantly, with a market size of 137.5 billion yuan in 2024, reflecting a 17.72% increase from the previous year [1][13] - The pharmaceutical manufacturing sector is also expanding, with the number of enterprises reaching 9,793 in 2024, a 4.05% increase, and total sales revenue of 25,298.5 billion yuan, a 0.37% increase [11] Competitive Landscape - The CSO industry in China is characterized by a fragmented market with numerous participants, including major players like Yiteng Pharmaceutical, Shanghai Pharmaceuticals, Baiyang Pharmaceutical, and Jiuzhoutong [16] - Jiuzhoutong, leveraging its national distribution network, provides comprehensive promotional services and has established a significant market presence [16][18] - Shanghai Pharmaceuticals is a leading national pharmaceutical distributor with a diverse service platform, reporting total revenue of 275.3 billion yuan in 2024 [20] Future Trends - As competition in the pharmaceutical market intensifies, CSO firms will need to enhance their professional service capabilities in market research, product planning, academic promotion, and compliance management [22] - CSOs are expected to focus on personalized service offerings tailored to the specific needs of different pharmaceutical companies and products, including differentiated marketing strategies for innovative and generic drugs [22]

2024年度 环境、社会和公司治理（ESG）报告 ENVIRONMENTAL SOCIAL AND GOVERNANCE REPORT 以科技进步和品质服务引领美好生活 股票简称：中国医药 股票代码：600056 上海证券交易所发行上市 关于本报告 本报告是中国医药健康产业股份有限公司（以下简称 报告获取途径 "中国医药""公司""我们"）发布的第三份环境、社会和 公司治理（ESG）报告，本着客观、规范、透明和全面的原 则，详细披露了中国医药2024年在积极承担社会责任、 有效管理ESG风险与机遇等方面的具体举措、重点实 践、亮点案例和关键绩效，旨在积极回应利益相关方的 期望，并在未来更好地履行社会责任。 时间范围 本报告为年度报告，涵盖期间为2024年1月1日至12月 31日，与年度财务报告保持一致，部分内容可能追溯至 以往年份或具有前瞻性描述。 报告范围 本报告以中国医药为主体，包括下属分支机构、子公 司。除另做说明外，本报告范围与公司年度财务报告范 围保持一致。 编制依据 本报告主要参考国务院国有资产监督管理委员会《关于国有企业更好履行社会责任的指导意见》《提高央企控股上市公 司质量工作方案》《央企控股 ...

2024 年度"提质增效重回报"行动方案实施情况暨 2025 年度"提质增效重回报"行动方案 革，加快实业化步伐，着力稳增长、优布局、防风险、提质 效，医药工业加速升级，实现高端化智能化绿色化，医械业 务多点发力，加快形成一体化运营格局，医药商业协同发展， 增强服务能力稳住基本盘，国际业务积极进取，深耕细作属 地化合规经营，加速实现投资突破，坚持内涵增长与外延发 展并重，加快把公司建设成为"科、工、贸、技、服"一体 化发展的医药及医疗器械健康产业集团，为实现"十五五" 良好开局筑牢坚实基础。 中国医药健康产业股份有限公司（以下简称"公司"） 紧紧围绕中央经济工作会议和中央金融工作会议精神，积极 响应上海证券交易所《关于开展沪市公司"提质增效重回报" 专项行动的倡议》，制定了2024年度"提质增效重回报"行 动方案，于2024年4月11日经公司第九届董事会第11次会议 审议通过后披露，并大力开展落实，着力提高经营质效、治 理质效、信披质效和回报投资者质效，推动公司高质量发展。 2025年，为进一步充分发挥上市公司平台作用，与股东共享 发展红利，公司制定2025年度"提质增效重回报"行动方案。 现将2024年度" ...